In Hyp mice, a murine model that replicates the XLH phenotype, early treatment with an FGF23‐neutralizing antibody was shown to increase predentin formation and mineralization.(24) It should be also noted that individuals with FG23 deficiency have increased dentin formation and reduced pulp chamber volume.(29) Several biological mechanisms may contribute to the improvement of dentin mineralization with burosumab. Here, FGF23 is linked to hyperinsulinemic hypoglycemia, familial, 4.